 | | PRD_001175 | | Name: | P-((((benzyloxy)carbonyl)amino)methyl)-N-((S)-1-(isobutylamino)-4-methyl-1-oxopentan-2-yl)phosphonamidic acid | | Formula: | C19 H32 N3 O5 P | | Definition date: | 2014-04-02 | | Last modified: | 2017-09-14 |
|
 | | PRD_001177 | | Name: | P-((((benzyloxy)carbonyl)amino)methyl)-N-((S)-4-methyl-1-oxo-1-(phenethylamino)pentan-2-yl)phosphonamidic acid | | Formula: | C23 H32 N3 O5 P | | Definition date: | 2014-04-02 | | Last modified: | 2017-09-14 |
|
 | | PRD_001178 | | Name: | P-((((benzyloxy)carbonyl)amino)methyl)-N-((S)-4-methyl-1-oxo-1-(propylamino)pentan-2-yl)phosphonamidic acid | | Formula: | C18 H30 N3 O5 P | | Definition date: | 2014-04-02 | | Last modified: | 2017-09-14 |
|
 | | PRD_001179 | | Name: | P-((((benzyloxy)carbonyl)amino)methyl)-N-((S)-4-methyl-1-(((S)-2-methylbutyl)amino)-1-oxopentan- 2-yl)phosphonamidic
acid | | Formula: | C20 H34 N3 O5 P | | Definition date: | 2014-04-02 | | Last modified: | 2017-09-14 |
|
 | | PRD_001180 | | Name: | P-((((benzyloxy)carbonyl)amino)methyl)-N-((S)-1-((3,3-dimethylbutyl)amino)-4-methyl-1-oxopentan-2-yl)phosphonamidic
acid | | Formula: | C21 H36 N3 O5 P | | Definition date: | 2014-04-02 | | Last modified: | 2017-09-14 |
|
 | | PRD_001182 | | Name: | P-((((benzyloxy)carbonyl)amino)methyl)-N-((S)-4-methyl-1-(neopentylamino)-1-oxopentan-2-yl)phosphonamidic acid | | Formula: | C20 H34 N3 O5 P | | Definition date: | 2014-04-02 | | Last modified: | 2017-09-14 |
|
 | | PRD_001183 | | Name: | P-((((benzyloxy)carbonyl)amino)methyl)-N-((S)-1-(isopentylamino)-4-methyl-1-oxopentan-2-yl)phosphonamidic acid | | Formula: | C20 H34 N3 O5 P | | Definition date: | 2014-04-02 | | Last modified: | 2017-09-14 |
|
 | | PRD_001218 | | Name: | Dityromycin | | Formula: | C67 H88 N10 O16 | | Description: | DITYROMYCIN WAS CLARIFIED TO BE COMPOSED OF N-MEVAL, PRO, VAL, PHENYLGLYCINE, CH3NH2, N,N-ME2THR AND DI-ALPHA-AMINO ACID CONTAINING DIPHENYLETHER MOIETY. | | Definition date: | 2014-04-02 | | Last modified: | 2014-04-02 |
|
 | | PRD_001064 | | Name: | N-(tert-butylcarbamoyl)-3-methyl-L-valyl-(4R)-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-4-[(7-methoxy-2-phenylquinolin-4-yl)oxy]-L-prolinamide | | Formula: | C38 H47 N5 O7 | | Definition date: | 2014-03-26 | | Last modified: | 2023-11-03 |
|
 | | PRD_001142 | | Name: | tyrocidine A | | Formula: | C66 H87 N13 O13 | | Definition date: | 2014-03-19 | | Last modified: | 2014-03-19 |
|
 | | PRD_001066 | | Name: | Muramyl tetrapeptide | | Formula: | C30 H53 N8 O13 | | Definition date: | 2014-03-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_001184 | | Name: | Dimethyl FK228 | | Formula: | C26 H42 N4 O6 S2 | | Description: | DIMETHYL FK228 IS THE REDUCED AND MODIFIED FORM OF ROMIDEPSIN. THE DISULFIDE INTRAMOLECULAR LINKAGE OF ROMIDEPSIN IS BROKEN, AND BOTH SULFHYDRYL GROUPS ARE METHYLATED. | | Definition date: | 2014-03-05 | | Last modified: | 2023-11-03 |
|
 | | PRD_001219 | | Name: | Lantibiotic 107891 | | Formula: | C94 H127 Cl N26 O26 S5 | | Description: | NAI-107 IS A TETRACYCLIC PEPTIDE. POST TRANSLATIONAL MATURATION OF LANTIBIOTICS INVOLVES THE ENZYMIC CONVERSION OF THR, AND SER INTO DEHYDRATED AA AND THE FORMATION OF THIOETHER BONDS WITH CYSTEINE. THE CARBOXY-TERMINAL BETA-METHYLLANTHIONINE UNDERGOES DECARBOXYLATION. THIOETHER BONDS WITH CYSTEINE RESULT IN FOUR RINGS. THIS IS FOLLOWED BY MEMBRANE TRANSLOCATION AND CLEAVAGE OF THE MODIFIED PRECURSOR. | | Definition date: | 2014-03-05 | | Last modified: | 2014-03-05 |
|
 | | PRD_000896 | | Name: | MM-402 | | Formula: | C31 H51 N8 O5 | | Definition date: | 2014-02-19 | | Last modified: | 2023-11-03 |
|
 | | PRD_000897 | | Name: | MM-401 | | Formula: | C29 H47 N8 O5 | | Definition date: | 2014-02-19 | | Last modified: | 2023-11-03 |
|
 | | PRD_001104 | | Name: | cyclic peptide S2iL5 | | Formula: | C90 H126 F3 N27 O23 S | | Definition date: | 2014-02-19 | | Last modified: | 2014-02-19 |
|
 | | PRD_001185 | | Name: | CONANTOKIN BK-B | | Formula: | C46 H64 N10 O25 | | Definition date: | 2014-02-19 | | Last modified: | 2014-02-19 |
|
 | | PRD_001135 | | Name: | (CBZ)NPQ(B27) peptide | | Formula: | C26 H38 N6 O8 S | | Definition date: | 2014-02-12 | | Last modified: | 2014-02-12 |
|
 | | PRD_001200 | | Name: | N-[(benzyloxy)carbonyl]-L-leucyl-N-{(1R,2S)-1-hydroxy-4-methyl-1-[(2R)-2-methyloxiran-2-yl]pentan-2-yl}-L-leucinamide | | Formula: | C29 H47 N3 O6 | | Definition date: | 2014-02-12 | | Last modified: | 2017-09-14 |
|
 | | PRD_001201 | | Name: | N-[(benzyloxy)carbonyl]-L-leucyl-N-[(2R,3S,4S)-1,3-dihydroxy-2,6-dimethylheptan-4-yl]-L-leucinamide | | Formula: | C29 H49 N3 O6 | | Definition date: | 2014-02-12 | | Last modified: | 2023-11-03 |
|
 | | PRD_001205 | | Name: | N-[(benzyloxy)carbonyl]-L-leucyl-N-[(2S,3S)-2-hydroxy-5-methyl-1-oxo-1-(phenylamino)hexan-3-yl]-L-leucinamide | | Formula: | C33 H48 N4 O6 | | Definition date: | 2014-02-12 | | Last modified: | 2017-09-14 |
|
 | | PRD_001206 | | Name: | N-[(benzyloxy)carbonyl]-L-leucyl-N-[(3S)-5-methyl-1-(methylsulfonyl)hexan-3-yl]-L-leucinamide | | Formula: | C28 H47 N3 O6 S | | Definition date: | 2014-02-12 | | Last modified: | 2017-09-14 |
|
 | | PRD_001207 | | Name: | N-[(benzyloxy)carbonyl]-L-leucyl-N-[(2R,3S)-1,2-dihydroxy-5-methylhexan-3-yl]-L-leucinamide | | Formula: | C27 H45 N3 O6 | | Definition date: | 2014-02-12 | | Last modified: | 2017-09-14 |
|
 | | PRD_001210 | | Name: | N-[(benzyloxy)carbonyl]-L-leucyl-N-[(2S)-1-hydroxy-4-methylpentan-2-yl]-L-leucinamide | | Formula: | C26 H43 N3 O5 | | Definition date: | 2014-02-12 | | Last modified: | 2017-09-14 |
|
 | | PRD_001166 | | Name: | bicyclic peptide UK749 | | Formula: | C71 H108 N25 O20 S3 | | Definition date: | 2014-02-05 | | Last modified: | 2014-02-05 |
|
